- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06024889
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
Intravenous (IV) loop diuretics have been a key component in treating pulmonary edema since the 1960s and has a Class 1 recommendation in the 2021 guidelines for acute heart failure. However, no randomized clinical trials have investigated loop diuretics versus other interventions for acute heart failure, and clinical knowledge of the hemodynamic effects of furosemide is based in studies from the 1970s. In this study, we aim to assess the acute effect of furosemide on cardiac filling pressures and pulmonary congestion.
Hypothesis:
Administration of furosemide induces a hyperacute (within 30 minutes) lowering of cardiac filling pressures and pulmonary congestion before significant diuresis occurs.
Design:
A prospective, interventional study including 20 patients admitted due to a clinical diagnosis of acute heart failure with pulmonary congestion.
Intervention:
80 mg of furosemide is administered IV. Measurements include blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS*, ultrasound examination of heart and lungs, and assessment of cardiac filling pressures with doppler and strain analysis. Measurements are repeated at several time points until 6 hours have passed.
Study Overview
Detailed Description
Prospective observational study of the acute and subacute effects of furosemide in patients with acute heart failure.
After inclusion, 80 mg of furosemide is administered IV.
Measurements include blood pressure, peripheral oxygen saturation, pulmonary fluid content, ultrasound examination of heart and lungs, and assessment of cardiac filling pressures with doppler and strain analysis. Measurements are repeated at several time points until 6 hours have passed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Johannes Grand
- Phone Number: +4538623862
- Email: johannes.grand@regionh.dk
Study Contact Backup
- Name: Nora Chaidi
- Phone Number: +4538623862
- Email: nora.el.caidi@regionh.dk
Study Locations
-
-
Capital Region Of Denmark
-
Copenhagen, Capital Region Of Denmark, Denmark, 2650
- Amager-Hvidovre Hospital
-
Contact:
- Johannes Grand, MD, PhD, MPH
- Email: johannes.grand@regionh.dk
-
Contact:
- Nora Caidi
- Email: nora.el.caidi@regionh.dk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Clinical diagnosis of acute heart failure requiring hospitalization
- Systolic blood pressure ≥100 mmHg
- Oxygen saturation <94% or need of oxygen
- Confirmed pulmonary congestion on x-ray or ReDS
Exclusion Criteria:
- More than 40 mg iv furosemide within the last three hours before randomization, including prehospital administration
- Ongoing ventricular taky- or brady-arrythmias or supraventricular arrhythmias with HR > 180 or < 40 bpm.
- Known chronic obstructive lung disease
- Pacemaker or ICD on the right side
- Congenital heart malformations or intra-thoracic mass that would affect the right lung anatomy (e.g. dextrocardia, lung carcinoma)
- Wounds, burns, healing tissue, skin infection or recent skin graft or flap where the sensors should be attached to the skin
- Height less than 155 cm or higher than 200 cm
- BMI of less than 18 or more than 38
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Furosemide
80 mg of furosemide is administered IV
|
Intravenous administration of 80 mg furosemide is followed by assessing blood pressure, peripheral oxygen saturation, pulmonary fluid content by ReDS*, and ultrasound examination of heart and lungs, including assessment of filling pressures with doppler and strain analysis.
These measurements are repeated at multiple time points until 6 hours have elapsed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary fluid content
Time Frame: From the time 0 to 30 minutes
|
Remote dielectric sensing (ReDS) is a non-invasive electromagnetic-based tool that measures absolute lung fluid content and gives the fluid content in a proportional value ranging from 0-100 percent. 20-35% represent normal values. The primary outcome will be change in pulmonary fluid content after administration of furosemide |
From the time 0 to 30 minutes
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Johannes Grand, Department of cardiology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-23029822
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Heart Failure
-
Idorsia Pharmaceuticals Ltd.CompletedAcute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart FailureUnited States, United Kingdom, Israel, Switzerland, Austria, Denmark, France, Germany, Greece, Poland
-
Idorsia Pharmaceuticals Ltd.CompletedAcute Heart Failure | Acute Decompensation of Chronic Heart Failure | New Onset of Heart FailureUnited States, Hungary, Australia, Czechia, Germany, Italy, Norway, United Kingdom
-
Abiomed Inc.RecruitingHeart Diseases | Acute Decompensated Heart Failure | Congestive Heart Failure | Acute Heart FailureUnited States
-
Shanghai Chest HospitalUnknownAcute Renal Failure | Acute Heart FailureChina
-
Magenta Medical Ltd.TerminatedCongestive Heart Failure | Heart Failure, Congestive | Acute Heart FailureCroatia, Belgium, Serbia
-
University Medical Center GroningenCompletedHeart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteNetherlands
-
Jordan Cardio Vascular Research GroupRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureJordan
-
Azienda Ospedaliera Città della Salute e della...Caretek S.r.l. Turin, Italy; Santer Reply S.p.A. Milan, ItalyUnknownHeart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteItaly
-
University Hospital, Clermont-FerrandHospices Civils de Lyon; University Hospital, Grenoble; Hôpital de la Croix-Rousse and other collaboratorsRecruitingHeart Failure | Chronic Heart Failure | Acute Heart FailureFrance
-
Clinica Alemana de SantiagoNot yet recruitingDecompensated Heart Failure | Heart Failure Acute
Clinical Trials on Furosemide Injection
-
Johns Hopkins UniversityscPharmaceuticals, Inc.Completed
-
Chiang Mai UniversityRecruiting
-
SQ Innovation, Inc.Accel Clinical ServicesCompleted
-
Jan Kochanowski UniversityRecruiting
-
Indonesia UniversityRecruitingAcute Kidney Injury Due to SepsisIndonesia
-
Todd M Koelling, MDscPharmaceuticals, Inc.WithdrawnAcute Decompensated Heart FailureUnited States
-
King Chulalongkorn Memorial HospitalRecruitingKidney Transplant; Complications | Delayed Graft Function | Kidney FunctionThailand
-
scPharmaceuticals, Inc.Completed
-
scPharmaceuticals, Inc.Completed